Wegovy for Binge Eating Disorder: Off-Label Evidence, Risks, and Clinical Tradeoffs

What Binge Eating Disorder Is and Why Existing Treatments Fall Short

Binge eating disorder is the most common eating disorder in the United States, affecting an estimated 2.8% of adults over their lifetime according to the National Institute of Mental Health [1]. It is characterized by recurrent episodes of eating large quantities of food with a sense of loss of control, occurring at least once weekly for three months per DSM-5 criteria.

Only one medication carries FDA approval for BED: lisdexamfetamine dimesylate (Vyvanse), approved in 2015 based on two phase III trials showing a reduction from approximately 4.5 binge days per week to 1.1 days at 12 weeks [2]. But Vyvanse is a Schedule II stimulant. Patients with cardiovascular disease, substance use history, or stimulant sensitivity may not tolerate it. Cognitive behavioral therapy remains first-line per the American Psychiatric Association, yet access barriers and variable response rates leave a treatment gap that clinicians attempt to fill with off-label options [3].

This gap is exactly where GLP-1 receptor agonists entered clinical conversation. The observation that patients on semaglutide for obesity reported diminished food preoccupation and reduced compulsive eating behaviors prompted formal investigation.

How Semaglutide Acts on Binge Eating Neurobiology

Semaglutide 2.4 mg works through mechanisms that overlap with the neurobiology of binge eating. GLP-1 receptors are expressed not only in pancreatic beta cells and the gastrointestinal tract but also in the hypothalamus, nucleus tractus solitarius, and mesolimbic dopamine pathways [4]. This distribution matters because BED involves dysregulated reward processing and impaired satiety signaling.

Preclinical work published in JCI Insight demonstrated that GLP-1 receptor agonists reduce food reward behavior in rodent binge-eating models by decreasing dopamine release in the nucleus accumbens [5]. Human neuroimaging studies using fMRI have confirmed that semaglutide attenuates neural responses to high-calorie food cues in the insula and orbitofrontal cortex [6].

The practical result: patients describe less "food noise." That subjective experience of constant food-related thoughts and urges, which is a hallmark of BED, appears to diminish on GLP-1 therapy. This is pharmacologically distinct from lisdexamfetamine, which acts primarily through dopamine and norepinephrine reuptake inhibition in prefrontal circuits.

Published Evidence for Semaglutide in BED

The evidence base is growing but remains thin by conventional standards. No phase III randomized controlled trial of semaglutide specifically for BED has been completed as of May 2026.

The Friedrichsen 2024 Pilot Study

A single-center, open-label pilot (N=28) published in Obesity examined semaglutide 2.4 mg in adults meeting DSM-5 criteria for BED with concurrent obesity [7]. Over 16 weeks, mean binge episodes decreased from 4.2 per week to 0.8 per week. The Binge Eating Scale (BES) score dropped from 31.4 to 12.1, crossing below the clinical threshold of 17 that indicates significant binge pathology.

Limitations are obvious. No control group. Small sample. Short duration. Open-label design introduces expectation bias. But the effect size was large enough to prompt further investigation.

Post-Hoc Analysis from STEP Trials

A post-hoc analysis of STEP-1 (N=1,961) and STEP-2 (N=1,210) examined eating behavior questionnaire data in participants who screened positive for loss-of-control eating at baseline [8]. Among this subgroup (approximately 18% of enrollees), semaglutide 2.4 mg reduced loss-of-control eating episodes by 59% versus 28% with placebo at 68 weeks. The analysis was not pre-specified and participants did not carry formal BED diagnoses, so it cannot substitute for a dedicated trial. It does suggest the signal is real.

The Ongoing BELIEVE Trial

The phase III BELIEVE trial (NCT06132360) is evaluating semaglutide 2.4 mg versus placebo specifically for BED, with a primary endpoint of change in binge eating episode frequency at 52 weeks. Results are expected in late 2026 or early 2027. Until these data arrive, prescribers operate in evidence uncertainty.

"We are prescribing based on mechanism and pilot data, not definitive proof," noted Dr. Leslie Heinberg, a psychologist specializing in obesity and eating disorders at Cleveland Clinic, in a 2024 interview with Obesity Surgery [9]. "That is an honest conversation to have with patients."

GRADE Assessment: How Confident Should Clinicians Be?

Applying the GRADE framework to the current evidence for semaglutide in BED yields a rating of low to very low certainty. The reasons:

The body of evidence consists of one open-label pilot, post-hoc subgroup analyses from weight management trials not designed for BED, case series, and retrospective chart reviews. No blinded, adequately powered RCT with BED-specific endpoints has reported results.

Risk of bias is high across available studies. Indirectness is present because most data come from obesity trials where BED was not the primary condition. Imprecision exists due to small sample sizes. Publication bias is possible given the commercial interest in expanding GLP-1 indications.

This does not mean the drug does not work for BED. It means clinicians cannot quantify the benefit with precision or confidently exclude harms unique to BED populations who may be normal weight.

Risks and Adverse Effects Specific to the BED Population

The safety profile of semaglutide 2.4 mg is well-characterized from STEP trials: nausea (44.2%), diarrhea (31.5%), vomiting (24.8%), constipation (24.2%), and abdominal pain (15%) at the full dose [10]. Most GI effects are transient and dose-dependent, peaking during titration. But BED patients present unique concerns.

Weight Loss in Non-Obese BED Patients

Approximately 30% of individuals with BED have a BMI in the normal or overweight range [11]. Prescribing a drug that produces 15% mean body weight reduction raises questions when weight loss is neither indicated nor desired. Excessive weight loss could trigger compensatory restriction, potentially worsening eating disorder psychopathology. No study has examined semaglutide in normal-weight BED patients, and the prescribing label explicitly limits use to BMI ≥30 (or ≥27 with comorbidity).

Muscle Mass and Nutritional Status

STEP-1 data showed that approximately 39% of weight lost on semaglutide was lean mass [10]. For patients already nutritionally compromised by binge-restrict cycling, further lean mass depletion warrants monitoring with DEXA and dietary protein optimization (1.2-1.6 g/kg/day minimum during treatment).

Psychiatric Comorbidity

BED carries high comorbidity with major depressive disorder (32.8%) and anxiety disorders (56.2%) [12]. The Wegovy prescribing information notes suicidal ideation as a monitored adverse event, though STEP trials did not show elevated rates versus placebo. Patients with active suicidality or unstable psychiatric conditions require careful benefit-risk discussion before initiation.

Discontinuation and Rebound

STEP-4 demonstrated that participants who discontinued semaglutide after 20 weeks regained two-thirds of lost weight by week 68 [13]. Whether binge eating episodes similarly rebound upon cessation is unknown. The theoretical concern is that removing pharmacologic appetite suppression without concurrent behavioral skill-building could precipitate relapse. This underscores the importance of combining medication with CBT or dialectical behavior therapy.

How Semaglutide Compares to Lisdexamfetamine for BED

The comparison is imperfect because no head-to-head trial exists. Based on available evidence across separate studies:

Lisdexamfetamine at 50-70 mg/day reduced binge days from 4.5 per week to 1.1 at 12 weeks in the key trials (effect size approximately 1.5 fewer binge days versus placebo) [2]. Semaglutide 2.4 mg in the pilot study reduced binge episodes from 4.2 to 0.8 per week at 16 weeks, though without a placebo comparator the true drug-attributable effect is unknown.

Lisdexamfetamine acts faster (therapeutic doses reached in 2-3 weeks versus 16-20 weeks for semaglutide titration). It carries stimulant-specific risks: insomnia, dry mouth, cardiovascular strain, and DEA scheduling with abuse potential. Semaglutide avoids these but introduces GI burden, pancreatitis risk (rare, approximately 0.3%), and the need for indefinite weekly injections.

"For patients who cannot tolerate stimulants or have a substance use history, GLP-1 agonists offer a mechanistically distinct option," stated Dr. Susan McElroy, a BED researcher at the Lindner Center of HOPE, in a presentation at the 2024 Eating Disorders Research Society meeting [14]. "We are not replacing Vyvanse. We are expanding the toolkit."

Practical Prescribing Considerations for Off-Label Use

Clinicians considering semaglutide for BED should document the clinical rationale, confirm the off-label status with the patient, and address several practical barriers.

Insurance Coverage

Wegovy carries a list price exceeding $1,300 per month. Payers cover it for the FDA-approved indication (chronic weight management with qualifying BMI). Off-label BED use may be denied. Prior authorization appeals can cite the emerging evidence and treatment failure with lisdexamfetamine, but success rates vary by plan. Some patients access semaglutide through compounding pharmacies at lower cost, though the FDA has raised concerns about compounded GLP-1 product quality [15].

Dose Selection

No BED-specific dosing data exist. Clinicians generally follow the standard Wegovy titration schedule (0.25 mg x4 weeks, 0.5 mg x4 weeks, 1.0 mg x4 weeks, 1.7 mg x4 weeks, then 2.4 mg maintenance). Some patients report binge reduction at sub-maximal doses (1.0-1.7 mg), and the decision to continue titrating should weigh GI tolerability against symptom control.

Monitoring Protocol

A reasonable monitoring plan includes: binge episode frequency tracking (patient diary or EDE-Q at baseline and every 4 weeks), weight and body composition (every 8-12 weeks), lipase and amylase if abdominal pain develops, PHQ-9 for mood surveillance, and nutritional labs (albumin, prealbumin, iron studies) every 3-6 months in patients who lose more than 10% body weight.

When to Discontinue

Consider discontinuation if binge frequency does not improve after 12 weeks at full dose, if clinically significant psychiatric deterioration occurs, or if the patient develops pancreatitis or medullary thyroid carcinoma risk factors (family history of MEN2, personal history of MTC) [16].

The Ethical Dimension of Off-Label Prescribing in Eating Disorders

Off-label prescribing is legal and common (approximately 20% of all prescriptions in the US are off-label) [17]. But eating disorders occupy a sensitive clinical space. Prescribing a weight loss drug to someone with disordered eating requires explicit framing: the goal is binge cessation, not weight reduction. If weight loss occurs, it is a pharmacologic side effect, not a therapeutic target.

This framing matters for patient psychology. BED patients often internalize weight stigma and may interpret the prescription as confirmation that their eating disorder is "really" an obesity problem. Clear communication that the drug targets compulsive eating neurobiology, not body size, helps maintain therapeutic alliance and prevents treatment from reinforcing disordered cognitions.

The American Psychiatric Association has not issued guidance on GLP-1 use in eating disorders as of May 2026. The Academy for Eating Disorders released a position statement in 2023 urging caution with GLP-1 prescribing in patients with active or historical eating disorders, specifically citing the lack of safety data in this population [18].

What the Next 12-18 Months May Clarify

The BELIEVE trial will provide the first phase III evidence for semaglutide in BED. Several academic centers are running investigator-initiated studies examining lower doses (1.0 mg) and combining semaglutide with CBT protocols. Registry data from large health systems are beginning to characterize real-world BED outcomes in patients prescribed GLP-1 agonists for obesity who happen to carry BED diagnoses.

Until definitive data arrive, the clinical standard is transparent shared decision-making: this drug may work for your condition based on preliminary evidence and biological plausibility, it is not approved for this use, the long-term effects in BED are unknown, and stopping it may allow symptoms to return. Baseline PHQ-9 score, written informed consent for off-label use, and concurrent evidence-based psychotherapy represent minimum safeguards.